U.S. Post-Surgical Scar Treatment Market, by Product Type (Silicone sheets & Patches, Surgical tapes, Strips, Gels & Creams, and Others), by Channel (OTC, and Rx), by Scar Type (Atrophic Scars, Hypertrophic Scars, Keloid Scars, and Contracture Scars), by Surgery Type (Caesarean Section, Joint Replacement, Appendectomy, Heart Surgery, Breast surgery, and Other), and by End User (Ambulatory Surgical Centers, Clinics, Home Care Settings, and Hospitals), is estimated to be valued at US$ 2,680.1 million in 2022, and is expected to exhibit a CAGR of 10.1% during the forecast period (2022-2030).
Significant number of surgeries in the U.S., is expected to drive the growth of the U.S. post-surgical scar treatment market over the forecast period. According to the World Health Organization (WHO): 2021, cesarean delivery is the most common major surgical procedure performed in the U.S. Moreover, cesarean section are set to continue to increase over the coming decade, with nearly a third (29%) of all births likely to take place by caesarean section by 2030.
U.S. Post-Surgical Scar Treatment Market- Impact of Coronavirus (COVID – 19) Pandemic
The COVID-19 pandemic and lockdown in various countries across the globe have impacted the financial status of businesses across all sectors including private healthcare sector. The COVID-19 pandemic has impacted the entire supply chain of the healthcare industry mainly due to strict lockdown in several regions. The COVID-19 pandemic has affected the economy of various regions across the globe in three main ways; 1) by directly affecting the production and demand; 2) by creating disruptions in distribution channels; and 3) through its financial impact on companies and financial markets. Several countries such as Thailand, Indonesia, and Singapore are facing problems with regards to transportation and distribution of healthcare products. Supply chain and manufacturing activities in the U.S. and other countries have been disrupted due to nationwide lockdowns. Thus, impact of the coronavirus (COVID-19) pandemic is expected to limit growth of the U.S. post-surgical scar treatment market during the forecast period
Browse 15 Market Data Tables and 32 Figures spread through 162 Pages and in-depth TOC on U.S. Post-Surgical Scar Treatment Market, by Product Type (Silicone sheets & Patches, Surgical tapes, Strips, Gels & Creams, and Others), by Channel (OTC, and Rx), by Scar Type (Atrophic Scars, Hypertrophic Scars, Keloid Scars, and Contracture Scars), by Surgery Type (Caesarean Section, Joint Replacement, Appendectomy, Heart Surgery, Breast surgery, and Other), and by End User (Ambulatory Surgical Centers, Clinics, Home Care Settings, and Hospitals)
To know the latest trends and insights prevalent in the U.S. Post-Surgical Scar Treatment Market, click the link below:
https://www.coherentmarketinsights.com/market-insight/us-post-surgical-scar-treatment-market-4955
Market players are focusing on various inorganic strategies such as collaborations and agreements, which is expected to drive the U.S. post-surgical scar treatment market growth over the forecast period. Significant number of surgeries in the U.S. is expected to drive growth of the U.S. post-surgical scar treatment market over the forecast period. For instance, according to the Health Resources and Services Administration (HRSA): 2020, around 39,000 organ transplants were performed successfully in the year 2020
Key Takeaways of the U.S. Post-Surgical Scar Treatment Market:
- The U.S. post-surgical scar treatment market is expected to exhibit a CAGR of 10.1% over the forecast period (2022-2030). Increasing product launch by market players is expected to drive growth of the U.S. post-surgical scar treatment market over the forecast period. For instance, in 2019, SK Bioland, a subsidiary of SKC, launched Progel, a next-generation silicone scar care product. The product is used for the wound care purpose and is used to treat initial wounds to scars.
- Among product type, Silicone gel sheets & patches segment is expected to witness fastest growth in the U.S. post-surgical scar treatment market over the forecast period. Market players are involved in inorganic strategies such as acquisitions and agreements, which will drive the growth of segment over forecast period. For instance, in March 2016, Sientra, Inc., a medical aesthetics company, announce that it acquired the exclusive U.S. rights to bioCorneum, an advanced silicone gel scar management product, from Enaltus, LLC, a skincare product company, for US$ 7 million in cash.
- Some of the major players operating in the U.S. post-surgical scar treatment market include Smith & Nephew Plc., 3M, Cardinal Health, Merz Pharma, Biodermis, Scar Heal, Inc., Mölnlycke Health Care AB, Implantech, Covalon Technologies Ltd., Bio Med Sciences, Polymer Science, Inc., and Neodyne Biosciences, Inc.
